| __timestamp | Alnylam Pharmaceuticals, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 22223073 |
| Thursday, January 1, 2015 | 276495000 | 6966842 |
| Friday, January 1, 2016 | 382392000 | 9000499 |
| Sunday, January 1, 2017 | 390635000 | 13741186 |
| Monday, January 1, 2018 | 505420000 | 19040000 |
| Tuesday, January 1, 2019 | 655114000 | 23559000 |
| Wednesday, January 1, 2020 | 654819000 | 31931000 |
| Friday, January 1, 2021 | 792156000 | 44981000 |
| Saturday, January 1, 2022 | 883015000 | 54234000 |
| Sunday, January 1, 2023 | 1004415000 | 63806000 |
| Monday, January 1, 2024 | 1126232000 |
Unveiling the hidden dimensions of data
In the ever-evolving world of pharmaceuticals, innovation is the key to staying ahead. Alnylam Pharmaceuticals, Inc. and Viking Therapeutics, Inc. are two companies that have shown a commitment to research and development (R&D) over the past decade. From 2014 to 2023, Alnylam has consistently outpaced Viking in R&D spending, with a staggering 428% increase, reaching over $1 billion in 2023. In contrast, Viking's R&D expenses grew by approximately 187%, peaking at $64 million in the same year.
This significant difference highlights Alnylam's aggressive investment strategy, which could be a driving force behind its innovative breakthroughs. Meanwhile, Viking's more conservative approach may reflect a different strategic focus. As the pharmaceutical landscape continues to change, these spending patterns offer valuable insights into each company's priorities and potential future trajectories.
Research and Development: Comparing Key Metrics for Amgen Inc. and Alnylam Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Viking Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Lantheus Holdings, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Viking Therapeutics, Inc.
Viking Therapeutics, Inc. or CRISPR Therapeutics AG: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs HUTCHMED (China) Limited
Research and Development Investment: Viking Therapeutics, Inc. vs Travere Therapeutics, Inc.
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs Xencor, Inc.